EzPlaz Freeze Dried Plasma FDA Approved
Defense Health Agency · DEFENSE HEALTH AGENCY
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HT942726QE015 in this department, oldest first.
- Aug 25, 2026 · this noticeSources Sought
- Sep 1, 2026Special NoticeOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This Sources Sought Notice (SSN) is for market research, information, and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Defense Health Agency Contracting Activity (DHACA) or the DHA Portfolio Acquisition Executive Medical Products (PAE MP). This SSN is being issued by DHACA on behalf of DHA PAE MP and is seeking sources to procure a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product. If capable sources are not identified through this notice, then DHACA intends to execute a firm-fixed price Indefinite Delive… (show all)
ry/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1 to Vascular Solutions LLC, 6464 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. The DHA PAE MP has a requirement for supply of an FDA approved FDP product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ�, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This SSN is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed five (8.5 x 11 inch) pages using a font size no smaller than 10-point. The Government will consider all capability statements received by the due date of this notice. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability statements are due by 3:00 PM local time, 1 September 2026. Capability statements shall be submitted by email ONLY as a Microsoft Word or Adobe PDF attachment to the following addresses: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil.
Who won similar work
8 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), same product/service code (PSC) 6505.
Single-winner award sizes (8): middle half $391K to $2.0M, median $882K; range $350K to $5.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 1 | $5.0M | Jan 29, 2026 |
| CARDINAL HEALTH 414, LLC · $CAH · $254.2B | 1 | $2.4M | Oct 1, 2026 |
| PROLACTA BIOSCIENCE, INC | 1 | $1.9M | Dec 4, 2024 |
| CENTRAL ADMIXTURE PHARMACY SERVICES, INC | 1 | $900K | Aug 12, 2026 |
| KEMP PROTEINS, LLC | 1 | $864K | Jul 11, 2025 |
| INO THERAPEUTICS LLC | 1 | $404K | Mar 12, 2025 |
| BOSTON SCIENTIFIC CORP · $BSX · $21.0B | 1 | $350K | Aug 21, 2026 |
| AGILENT TECHNOLOGIES INC · $A · $7.4B | 1 | $350K | Oct 6, 2026 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- $CAH reported $254.2B revenue (fiscal year ending Jun 30, 2026). The median single-winner award in these 8 past awards, $882K, is under 0.1% of that. SEC filing
- $BSX reported $21.0B revenue (12 months to Jun 30, 2026). The median single-winner award in these 8 past awards, $882K, is under 0.1% of that. SEC filing
- $A reported $7.4B revenue (12 months to Jul 31, 2026). The median single-winner award in these 8 past awards, $882K, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 6, 2026AGILENT TECHNOLOGIES INC$350KIHC Reagents and SuppliesMateriality: <0.01% of $A revenue (Low) SEC
- Oct 1, 2026CARDINAL HEALTH 414, LLC$2.4MFDA-Approved Radiopharmaceutical Supplies and Cold KitsMateriality: <0.01% of $CAH revenue (Low) SEC
- Aug 21, 2026BOSTON SCIENTIFIC CORP$350KY-90 Glass TheraspheresMateriality: <0.01% of $BSX revenue (Low) SEC
- Aug 12, 2026CENTRAL ADMIXTURE PHARMACY SERVICES, INC$900KPre-Mixed IV Fluids, cardioplegic solutions, and specialized Total Parenteral NutritionNo listed company matched (Materiality N/A)
- Jan 29, 2026Novartis Pharmaceuticals Corporation$5.0MPluvicto and Lutathera 5 Year BPANo listed company matched (Materiality N/A)
- Jul 11, 2025KEMP PROTEINS, LLC$864KHybridoma Development Studies and Antibody ProductionNo listed company matched (Materiality N/A)
- Mar 12, 2025INO THERAPEUTICS LLC$404KNotice of Intent to Sole Source Neonatal Pediatric Inhaled Nitric Oxide (INO) GasNo listed company matched (Materiality N/A)
- Dec 4, 2024PROLACTA BIOSCIENCE, INC$1.9MPasteurized Human-Based milkNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff since 2024 (4 filings)
- 0 of their lobbyists list a past Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff job
- $60K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Armed Services, Senate Committee on Appropriations, Senate Committee on Armed Services
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 3 of the past winners are listed companies
- 5 insider buys and 8 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.